Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Vir Biotechnology, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.520 -- 00:00:05.666 Hello and welcome to Veer Biotechnology's third quarter 2025 financial results 00:00:05.666 -- 00:00:10.651 and corporate update call. As a reminder, this conference call is being recorded. 00:00:10.651 -- 00:00:14.175 At this time, all participants are in a listen-only mode. 00:00:14.175 -- 00:00:17.679 After the speaker's remarks, there will be a question and answer session. 00:00:17.679 -- 00:00:22.124 I will now turn the call over to Jason O'Byrne, Chief Financial Officer. 00:00:22.124 -- 00:00:23.525 Please go ahead. 00:00:23.525 -- 00:00:26.589 Thank you and good afternoon. With me today are Dr. 00:00:26.589 -- 00:00:30.653 Marianne DeBacker, our Chief Executive Officer, and Dr. 00:00:30.653 -- 00:00:33.996 Mark Eisner, our Chief Medical Officer. 00:00:33.996 -- 00:00:37.760 Before we begin, I would like to remind everyone that some of the statements we are making 00:00:37.760 -- 00:00:41.564 today are forward-looking statements under the securities laws. 00:00:41.564 -- 00:00:45.848 These forward-looking statements involve substantial risks and uncertainties that could 00:00:45.848 -- 00:00:51.053 cause our clinical development programs, future results, performance, or achievements 00:00:51.053 -- 00:00:56.358 to differ significantly from those expressed or implied by such forward-looking statements. 00:00:56.358 -- 00:01:01.258 These risks and uncertainties and risks associated with our business are described in 00:01:01.258 -- 00:01:06.365 the company's reports filed with the Securities and Exchange Commission, including forms 00:01:06.365 -- 00:01:10.190 10-K, 10-Q, and 8-K. 00:01:10.190 -- 00:01:14.436 I will now turn the call over to our CEO, Marianne DeBacker. 00:01:14.436 -- 00:01:16.876 Please go ahead. 00:01:17.560 ...